BIO.News Newsletter

On Friday, the House passed the Expanding Access to Capital Act (H.R. 2799), which would provide incentives to invest in innovation. We have details, plus how to register for BIO’s first-ever Agriculture and Environment Summit in D.C. (567 words, 2 minutes, 50 seconds)

Happy Friday. We have a look at what Biden said during the SOTU—and BIO’s reaction—and celebrate National Biobased Products Day and Women’s History Month. (634 words, 3 minutes, 10 seconds)

We’re gearing up for the State of the Union, where President Biden’s expected to talk about drug price controls. In the meantime, we review a pandemic preparedness hearing and what U.S. officials are saying about Mexico’s looming corn ban. (626 words, 3 minutes, 7 seconds)

An FDA advisory committee unanimously recommended a change in next year’s flu vaccine and BIO was on the scene when New Mexico Gov. Michelle Lujan Grisham signed the state’s clean fuel standard—plus, an exclusive look at John F. Crowley’s first day as BIO’s CEO. (586 words, 2 minutes, 55 seconds)

We have a quick video recap of yesterday’s White House listening session on PBMs, plus optimism about biotech IPOs and biotech fashion. (678 words, 3 minutes, 23 seconds)

It’s an exciting week, as we officially welcome John Crowley as BIO’s CEO. Meanwhile, we look at what happened at the WTO last week, and what’s ahead at the White House listening session on PBMs today. (623 words, 3 minutes, 6 seconds)

Happy March. We recap yesterday’s Rare Disease Day hearing—and the bipartisan support for a few key BIO priorities—and look at a few things you might have missed at the BIO CEO and Investor Conference. (552 words, 2 minutes, 45 seconds)

A leap year means we have an extra day in the month to talk about rare disease patients and R&D. Plus, Agriculture Secretary Tom Vilsack talked about biotech on the Hill and BIO’s David Thomas writes about the vaccine pipeline in International Business Times. (849 words, 4 minutes, 19 seconds)

BIO members and CEOs sent a letter to congressional leaders urging them to pass the ORPHAN Cures Act and support rare disease R&D. Plus, more highlights from the BIO CEO and Investor Conference, including what executives are saying about the policy outlook and AI. (676 words, 3 minutes, 22 seconds)

On Day 1 of the BIO CEO and Investor Conference, CEOs and experts explained why it’s a great time to invest in innovations such as gene therapy and vaccines. Meanwhile, the I am BIO Podcast launches its new season with a look at the first approved CRISPR-based gene therapy and its impact on sickle cell patients. (780 words, 3 minutes, 54 seconds)